Positive Data From Inflammatory Bowel Disease StudyTeva and Sanofi SA (NASDAQ:SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.The study demonstrated durable clinical efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease.The study involved 130 patients who initially responded to duvakitug in the induction phase, and both doses of duvakitug were well tolerated ...

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Paris and Pa ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2 ...

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of French drugmaker Sanofi is seen in Paris, France, January 9, 2026. REUTERS/Gonzalo Fuentes/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Sanofi SA]Follow[Eli Lilly and Co]Follow[Merck KGaA]FollowShow more companiesFeb 16 (Reuters) - French drugmaker Sanofi [(SASY.PA), opens ...

Core Insights - A universal RSV immunization program using Beyfortus (nirsevimab) significantly reduced RSV-related hospitalizations in infants during their second RSV season after immunization in their first season [1][3] Group 1: Study Findings - The NIRSE-GAL study in Galicia, Spain, demonstrated a 94.4% coverage rate with 11,796 out of 12,492 eligible infants immunized [2] - There was an 85.9% reduction in RSV-related lower respiratory tract infection (LRTI) hospitalizations during the first season [2][6] - Infants who received Beyfortus during infancy experienced a 55.3% reduction in hospitalizations during their second RSV season [2] - The study also reported a 78.2% reduction in RSV-related rehospitalizations and a 62.4% reduction in LRTI rehospitalizations during the second season [4] Group 2: Implications for Public Health - The findings support the hypothesis that early protection against RSV-related lung damage may have lasting benefits on respiratory health [4] - The results provide compelling data to inform infant immunization strategies and economic evaluation models [3] Group 3: About Beyfortus - Beyfortus is designed to protect all infants during their first RSV season, including those born healthy at term or preterm, and those with health conditions [9] - It is a long-acting monoclonal antibody with an extended half-life of 71 days, administered as a single dose [10] - Over 11 million infants have been immunized with Beyfortus across more than 45 countries since its launch [11]

Core Insights - A universal RSV immunization program using Beyfortus (nirsevimab) significantly reduced RSV-related hospitalizations in infants during their second RSV season after immunization in their first season [1][3] Group 1: Study Findings - The NIRSE-GAL study in Galicia, Spain, demonstrated a 94.4% coverage rate among 11,796 infants out of 12,492 eligible, with an 85.9% reduction in RSV-related lower respiratory tract infection hospitalizations during the first season [2][6] - Infants who received Beyfortus during infancy experienced a 55.3% reduction in hospitalizations during their second RSV season [2] - The study also reported a 78.2% reduction in RSV-related rehospitalizations and a 62.4% reduction in lower respiratory tract infection rehospitalizations during the second season [4] Group 2: Implications for Public Health - The findings support the hypothesis that early protection against RSV-related lung damage may have lasting benefits on respiratory health, influencing infant immunization strategies and economic evaluation models [3][4] - The study's results provide compelling population-based data that can inform public health policies regarding RSV immunization [3] Group 3: About Beyfortus - Beyfortus is designed to protect all infants during their first RSV season, including those born healthy at term or preterm, and those with health conditions that make them vulnerable to RSV disease [9] - It is a long-acting monoclonal antibody with an extended half-life of 71 days, administered as a single dose to newborns and infants [10] - Over 11 million infants have been immunized with Beyfortus across more than 45 countries, demonstrating its widespread acceptance and use [11]

业绩经营情况 公司预计2026年销售额按固定汇率计算将以高个位数百分比增长，业务每股收益增速略高于销售额，并 计划执行10亿欧元的股票回购计划。 公司基本面 经济观察网根据公开信息，赛诺菲安万特(SNY.US)在2026年初有几项值得关注的事件。 高管变动 2026年2月12日，公司突然宣布首席执行官保罗.哈德森将于本月离职，由贝伦.加里霍于2026年4月接 任，这一领导层变动可能影响公司未来的战略方向和研发效率。 同时，赛诺菲面临关键研发挑战，需要加速推进药物管线以替代其核心产品Dupixent(度普利尤单抗)， 该药占收入30%以上且专利将在2030年代初到期，而疫苗业务受美国政策影响可能继续承压。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - Sanofi has announced a leadership change, appointing Belén Garijo as the new CEO effective April 29, 2026, following the decision not to renew the mandate of current CEO Paul Hudson, which has led to a 4.5% drop in shares on February 12, 2026 [1][7]. Leadership Change - Paul Hudson's last day as CEO will be February 17, 2026, and Olivier Charmeil will serve as interim CEO until Garijo takes over [2]. - Belén Garijo, a Spanish national, previously served as CEO of Merck KGaA and has held roles at Abbott Laboratories and Sanofi [2]. Market Reaction - Investors have reacted negatively to the sudden CEO change, expressing concerns over Garijo's lack of a proven track record in leading large companies [3]. Stock Performance - Over the past six months, Sanofi's shares have declined by 4.1%, contrasting with a 28.4% increase in the industry [4]. Company Challenges - Sanofi is recognized as a major vaccine manufacturer and has a significant immunology drug, Dupixent, expected to generate around €22 billion in sales by 2030 [5]. - The company has faced setbacks in its research and development (R&D) efforts and pipeline innovation, which may have contributed to the decision for a leadership change [8][9]. - Sanofi has lagged in mergers and acquisitions compared to peers, impacting its growth and diversification [9]. Future Focus - Garijo's primary objectives will include enhancing R&D productivity, governance, and innovation, with the potential to turn around the company's fortunes [10].

Core Viewpoint - The decline in Sanofi's stock on February 12, 2026, is primarily attributed to sudden management changes and market concerns regarding its research and development prospects [1] Group 1: Executive Changes - On February 12, the company announced that CEO Paul Hudson would step down, with Merck executive Belén Garijo set to take over in April. This unexpected change was interpreted by the market as a sign of the board's impatience due to the lack of expected results from R&D investments. The stock closed down 4.51% at $47.03, with an intraday low of $46.71 [2] Group 2: Company Fundamentals - Despite a 7% year-over-year revenue growth in Q4 2025 (13.3% growth at constant exchange rates), investors are more concerned about the risks associated with a weak R&D pipeline. In the past 12 months, the experimental multiple sclerosis drug tolebrutinib failed in key trials, and the clinical trial data for the atopic dermatitis candidate amlitelimab has been mixed. Jefferies reported that the management change may indicate slow progress in R&D transformation [3][4] Group 3: Performance and Operations - Dupixent accounts for over 30% of the company's revenue, but its patent is set to expire in the early 2030s, and Sanofi has not clearly identified new drugs to replace its revenue scale. Analysts from AlphaValue noted that investors have lost patience with repeated R&D failures, and the leadership change has intensified short-term uncertainty [4] Group 4: Industry Policy and Environment - The vaccine business contributes nearly 20% to revenue, but sales in Q4 declined by 2.5% year-over-year. The company expects this business to continue declining in 2026, with negative impacts from the U.S. policy environment on vaccine promotion. Additionally, the broader market decline, with the Nasdaq index falling by 2.03%, exacerbated the stock's drop [5]